BioDelivery Sciences International Inc
F:BD5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Transtema Group AB
STO:TRANS
|
SE |
|
BHG Group AB
STO:BHG
|
SE |
|
Yash Pakka Limited
BSE:516030
|
IN |
|
Furuno Electric Co Ltd
TSE:6814
|
JP |
|
Narmada Agrobase Ltd
NSE:NARMADA
|
IN |
|
Shinpo Co Ltd
TSE:5903
|
JP |
|
Honda India Power Products Ltd
NSE:HONDAPOWER
|
IN |
|
Sanchuan Wisdom Technology Co Ltd
SZSE:300066
|
CN |
|
P
|
Permanent TSB Group Holdings PLC
ISEQ:PTSB
|
IE |
BioDelivery Sciences International Inc
Other Current Liabilities
BioDelivery Sciences International Inc
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
Other Current Liabilities
$666k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$1.4B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$4.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$25B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$8.5B
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
See Also
What is BioDelivery Sciences International Inc's Other Current Liabilities?
Other Current Liabilities
666k
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Other Current Liabilities amounts to 666k USD.
What is BioDelivery Sciences International Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-17%
